Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Apr;44(4):1108-11.
doi: 10.1128/AAC.44.4.1108-1111.2000.

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

E J Ernst  1 , M E Klepser, M A Pfaller
Affiliations

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

E J Ernst et al. Antimicrob Agents Chemother. 2000 Apr.

Abstract

The postantifungal effect (PAFE) of fluconazole, MK-0991, LY303366, and amphotericin B was determined against isolates of Candida albicans and Cryptococcus neoformans. Concentrations ranging from 0. 125 to 4 times the MIC were tested following exposure to the antifungal for 0.25 to 1 h. Combinations of azole and echinocandin antifungals (MK-0991 and LY303366) were tested against C. neoformans. Fluconazole displayed no measurable PAFE against Candida albicans or Cryptococcus neoformans, either alone or in combination with either echinocandin antifungal. MK-0991, LY303366, and amphotericin B displayed a prolonged PAFE of greater than 12 h against Candida spp. when tested at concentrations above the MIC for the organism and 0 to 2 h when tested at concentrations below the MIC for the organism.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
PAFE of MK-0991 in C. albicans 90028 following 0.5 h of exposure to the drug at various concentrations. ●, control; ○, 0.125 times the MIC; ▾, 0.25 times the MIC; ▿, 0.5 times the MIC; ■, 1 times the MIC; □, 2 times the MIC; ⧫, 4 times the MIC.
FIG. 2
FIG. 2
PAFE of AMB in C. albicans 90028 following 0.5 h of drug exposure at various concentrations. ●, control; ○, 0.125 times the MIC; ▾, 0.25 times the MIC; ▿, 0.5 times the MIC; ■, 1 times the MIC; □, 2 times the MIC; ⧫, 4 times the MIC.
FIG. 3
FIG. 3
PAFE of FLC, MK-0991, and LY303366 alone and in combination in C. neoformans 1450. ●, control; ○, FLC; ▾, MK-0991; ▿, LY303366; ■, FLC plus MK-0991; □, FLC plus LY303366.
See this image and copyright information in PMC

References

    1. Bartizal K, Gill C J, Abruzzo G K, Flattery A M, Kong L, Scott P M, Smith J G, Leighton C E, Bouffard A, Dropinski J F, Balkovec J. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) Antimicrob Agents Chemother. 1997;41:2326–2332. - PMC - PubMed
    1. Craig W A, Gudmundsson S. Postantibiotic effect. 4th ed. Baltimore, Md: Williams & Wilkins; 1996.
    1. Ernst E J, Klepser M E, Ernst M E, Messer S A, Pfaller M A. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis. 1999;33:75–80. - PubMed
    1. Ernst M E, Klepser M E, Wolfe E J, Pfaller M A. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn Microbiol Infect Dis. 1996;26:125–131. - PubMed
    1. Klepser M E, Ernst E J, Ernst M E, Messer S A, Pfaller M A. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother. 1998;42:1387–1391. - PMC - PubMed